IP Library Granted Patent US 10,583,134
Granted Patent B2
US 10,583,134 · App. 15/964,604 · Granted Mar 10, 2020

Methods and therapeutic combinations for treating tumors

Inventors: John Vasilakos (Woodbury, MN); Willem Overwijk (Houston, TX)
Assignees: 3M INNOVATIVE PROPERTIES COMPANY; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
A61K31/4745A61K9/0019A61K39/395A61K45/06A61P35/00A61K9/08A61K9/127A61K9/19A61K39/39558A61K47/10A61K47/44A61K2039/505C07K16/2818
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,134
App. No.
15/964,604
Granted
Mar 10, 2020
Kind
B2
Abstract

Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an Immune Response Modifier Compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds.

Claims (5)

1. A method of treating a tumor in a subject in need thereof, comprising administering a therapeutically effective amount of a PD-L1 antibody to the subject; and administering a therapeutically effective amount of an IRM compound to the subject; wherein the IRM compound is N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

2. A method of treating a tumor in a subject in need thereof, comprising administering a therapeutically effective amount of a CTLA-4 antibody to the subject; and administering a therapeutically effective amount of an IRM compound to the subject; wherein the IRM compound is N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

3. A method of treating a tumor in a subject in need thereof, comprising administering a therapeutically effective amount of a PD-L1 antibody to the subject; and administering a therapeutically effective amount of a CTLA-4 antibody to the subject; and administering a therapeutically effective amount of an IRM compound to the subject; wherein the IRM compound is N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

4. The method of any one of claims 1 - 3 , wherein N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is injected directly into the tumor.

5. The method of claim 4 , wherein the tumor is a breast cancer tumor, a bladder cancer tumor, a head and neck cancer tumor, a non-small cell lung cancer tumor, a small cell lung cancer tumor, a colorectal cancer tumor, a gastrointestinal stromal tumor, a gastroesophageal carcinoma, a renal cell cancer tumor, a prostate cancer tumor, a liver cancer tumor, a colon cancer tumor, a pancreatic cancer tumor, an ovarian cancer tumor, a lymphoma, or a cutaneous T-cell lymphoma, or a melanoma.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066333/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2018
From: OVERWIJK, WILLEM
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 045654/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2018
From: VASILAKOS, JOHN
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 045654/0764 →
Continuity (3)
Continuation 15500618
Provisional Application 62032149 · Aug 1, 2014
Related Publication 20180243287A1 · Aug 30, 2018